Edition:
India

People: Charles River Laboratories International Inc (CRL.N)

CRL.N on New York Stock Exchange

139.07USD
15 Nov 2019
Change (% chg)

$1.48 (+1.08%)
Prev Close
$137.59
Open
$138.00
Day's High
$139.18
Day's Low
$137.06
Volume
76,913
Avg. Vol
95,213
52-wk High
$148.97
52-wk Low
$103.00

Mackay, Martin 

Dr. Martin W Mackay Ph.D. serves as Independent Director of the company. Dr. Mackay is co-founder and Chief Executive Officer of Rallybio, a privately-held early-stage biotechnology company incorporated in January 2018. From May 2013 to June 2017, Dr. Mackay served as the Global Head of Research & Development at Alexion Pharmaceuticals, Inc. and from July 2010 to January 2013, Dr. Mackay served as the President of R&D at AstraZeneca PLC where he led the research and development organization and had overall accountability for delivering new products from its pipeline. Dr. Mackay's extensive experience leading research and development organizations at both global pharmaceutical and biotechnology companies provides us with a unique combination of expertise. Dr. Mackay has been a director since July 2017.

Basic Compensation

Total Annual Compensation, USD 60,000
Restricted Stock Award, USD 215,049
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 275,049

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

James Foster

14,450,800

David Smith

3,239,940

David Johst

5,269,400

William Barbo

2,576,390

Birgit Girshick

2,523,360

George Milne

305,049
As Of  29 Dec 2018